Literature DB >> 1506005

Different role of cytokine mediators in septic shock related to meningococcal disease and surgery/polytrauma.

A Waage1, A O Aasen.   

Abstract

So far, there has been a tendency towards a uniform concept of the role and kinetics of TNF and other cytokines in septic shock. However, our comparison of data from different groups of shock patients clearly demonstrates marked differences. On the one hand, the cytokine pattern in experimental septic shock and meningococcal disease has similarities which include early burst releases of TNF and IL-6. On the other hand, intensive care unit patients which includes patients with polytrauma, surgery, burns and other underlying diseases have a completely different pattern of appearance of TNF and IL-6 in the circulation. We have not been able to detect bioactive TNF in the circulation of these patients, whereas others have measured elevated levels of immunoreactive TNF. Bioactive IL-6 can be detected in serum; however, the levels are often fluctuating and there is no common pattern of appearance. These differences probably reflect differences in the release of endotoxin and the immunological status of the patients. TNF inhibitors and soluble TNF receptors probably play an important role. Experimental models for septic shock most commonly use administration of live bacteria or endotoxin to anesthesized healthy animals. This appears to be a good model for meningococcal disease, but not for intensive care unit patients.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1506005     DOI: 10.1111/j.1600-065x.1992.tb01416.x

Source DB:  PubMed          Journal:  Immunol Rev        ISSN: 0105-2896            Impact factor:   12.988


  14 in total

1.  Hemofiltration in septic patients is not able to alter the plasma concentration of cytokines therapeutically.

Authors:  M van Deuren; J W van der Meer
Journal:  Intensive Care Med       Date:  2000-09       Impact factor: 17.440

2.  Dynamic and transient remodeling of the macrophage IL-10 promoter during transcription.

Authors:  Xia Zhang; Justin P Edwards; David M Mosser
Journal:  J Immunol       Date:  2006-07-15       Impact factor: 5.422

Review 3.  Update on meningococcal disease with emphasis on pathogenesis and clinical management.

Authors:  M van Deuren; P Brandtzaeg; J W van der Meer
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

4.  Thaliporphine increases survival rate and attenuates multiple organ injury in LPS-induced endotoxaemia.

Authors:  Chin-Wei Chiao; Shoei-Sheng Lee; Chin-Chen Wu; Ming-Jai Su
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-15       Impact factor: 3.000

5.  Nitrite/nitrate oxide and cytokines changes in patients with surgical stress.

Authors:  Naoki Hirabayashi; Hiroshi Tanimura; Hiroki Yamaue
Journal:  Dig Dis Sci       Date:  2005-05       Impact factor: 3.199

6.  Organ injury and cytokine release caused by peptidoglycan are dependent on the structural integrity of the glycan chain.

Authors:  Anders E Myhre; Jon Fredrik Stuestøl; Maria K Dahle; Gunhild Øverland; Christoph Thiemermann; Simon J Foster; Per Lilleaasen; Ansgar O Aasen; Jacob E Wang
Journal:  Infect Immun       Date:  2004-03       Impact factor: 3.441

7.  Altered IL-10 levels in trauma patients' M phi and T lymphocytes.

Authors:  C L Miller-Graziano; A K De; K Kodys
Journal:  J Clin Immunol       Date:  1995-03       Impact factor: 8.317

8.  Patient cytokine response in transfusion-associated sepsis.

Authors:  S K McAllister; L A Bland; M J Arduino; S M Aguero; P N Wenger; W R Jarvis
Journal:  Infect Immun       Date:  1994-05       Impact factor: 3.441

Review 9.  Current status of meningococcal group B vaccine candidates: capsular or noncapsular?

Authors:  J Diaz Romero; I M Outschoorn
Journal:  Clin Microbiol Rev       Date:  1994-10       Impact factor: 26.132

10.  Blood lactate levels are better prognostic indicators than TNF and IL-6 levels in patients with septic shock.

Authors:  G Marecaux; M R Pinsky; E Dupont; R J Kahn; J L Vincent
Journal:  Intensive Care Med       Date:  1996-05       Impact factor: 17.440

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.